Van Well Daan sold $9K of SOPH
Van Well Daan (Chief Legal Officer) sold 1,224 shares of SOPHiA GENETICS SA (SOPH) at $7.73 on 2026-11-16 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
Because the sale is under a pre-arranged Rule 10b5-1 plan, it is generally treated as routine compliance-driven selling rather than new negative information.
Market read
Traders may note the insider sale for sentiment monitoring, but it does not introduce new operational, financial, or regulatory information.
What to watch
The article provides only one sale size and does not include any offsetting buys, broader insider activity trends, or changes in company guidance.
Background
The article is an SEC Form 4 insider transaction disclosure for SOPHiA GENETICS SA, reported by the Chief Legal Officer.
Ticker impact
SOPHiA GENETICS insider Van Well Daan, Chief Legal Officer, sold 1,224 shares at $7.7301 on a pre-arranged 10b5-1 plan.
Likely minimal impact; any short-term noise is more about trading optics than new company information.
The filing is an SEC Form 4 insider transaction and explicitly states a pre-arranged 10b5-1 plan, which typically reduces interpretive weight versus discretionary selling.
Market effects
No clear sector read-through from a single officer 10b5-1 sale.
None.
None.
Counterpoint
Even with a 10b5-1 plan, repeated insider selling can coincide with periods of weaker sentiment, so traders may still watch for follow-on transactions.
Key entities
- issuerSOPHiA GENETICS SA
Company whose insider transaction is disclosed on SEC Form 4.
- insiderVan Well Daan
Chief Legal Officer who sold shares under a pre-arranged 10b5-1 plan.



